

بسم الله الرحمن الرحيم



SALWA AKL



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم



SALWA AKL

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



SALWA AKL



بعض الوثائق الأصلية تالفة



SALWA AKL



بالرسالة صفحات

لم ترد بالأصل



SALWA AKL

**PLASMINOGEN ACTIVATOR INHIBITOR-1 AND FIBRINOGEN
IN ISCHAEMIC HEART DISEASE**

Thesis

B 17372

Submitted in partial fulfilment for the requirements
of the Msc Degree in General Medicine

By

Ibrahim Samy Tawfik

MB, BCh

د. طارق

Supervised by

Dr. Nadia El-Feky

Ass. Prof. of Internal Medicine

Kasr El-Aini

Faculty of Medicine

Dr. Taghrid Gaafar

Prof. of Clinical Pathology

Kasr El-Aini

Faculty of Medicine

Dr. Ahmed Saïd Abd El-Fatah

Lecturer of Internal Medicine

Kasr El-Aini

Faculty of Medicine

Faculty of Medicine

Cairo University

1993

ACKNOWLEDGMENT

First of all, I would like to express my sincerest gratitude to **Dr. Nadia EL-Feky**, Assistant Professor of Internal Medicine, Faculty of Medicine, Cairo University, for her support and help throughout the production of this work.

I am greatly indebted to **Dr. Taghrid Gaafer**, Assistant Professor of clinical Pathology, Faculty of Medicine, Cairo University, for her supervision, guidance and continuous support throughout the work.

I would like too to thank **Dr. Ahmed Saied**, Lecturer of Internal Medicine, Faculty of Medicine, Cairo University, for his guidance and for the time he spent and the effort he paid in directing, helping and encouraging me during this work.

0

CONTENTS

	Page
Introduction	1
Review of literature	2
Ischemic heart disease	2
Fibrinolytic system	15
Fibrinolysis and ischemic heart disease	28
Material and method	33
Results	41
Discussion	55
Summary	61
References	63
Arabic summary	-

INTRODUCTION

INTRODUCTION

Fibrinolytic activity is impaired in many patients with coronary artery disease. It has been suggested that impaired fibrinolysis has a pathogenic role in coronary artery disease. Impaired fibrinolysis could be caused by an increase in the activity of plasminogen activator inhibitor. However, some groups have reported only a very occasional and transient increase in plasminogen activator inhibitor in patients with coronary artery disease (Justo et al., 1988). Furthermore, PAI-1 plasma activity had not been compared to those of age matched non CAD patients but to those of normal young volunteers. Therefore, some authors have suggested that such a plasma PAI-1 elevation might mainly be due to the advanced age of patients with CAD (Huber et al., 1990).

Recent prospective investigations have reported that higher plasma fibrinogen concentration is associated with greater risk of cardiovascular disease (Aaron et al., 1991).

The aim of this work is to determine whether PAI-1 activity and plasma level of fibrinogen are implicated in the pathogenesis of chronic coronary heart disease, stressing on comparing the I.H.D. patients with a well defined age and sex matched control group.

REVIEW
OF
LITERATURE

ISCHEMIC HEART DISEASE

IHD is the generic designation for a group of closely related syndromes resulting from an imbalance between the supply and demand of the heart for oxygenated blood. Although ischemia also invokes reduced nutrient substrates and inadequate removal of metabolites, the critical factor is the insufficiency of oxygen (Robbins, 1989).

The heart may suffer a deficiency of oxygen when 1- An increase in demand outpaces the supply of oxygen, 2- Oxygen transport in the blood is diminished but 3- In over 90% of cases the root cause is reduction in coronary blood flow, owing largely to some complex dynamic interaction among fixed atherosclerotic narrowing of the subepicardial coronary arteries, intraluminal thrombosis overlying a ruptured or fissured plaque, vasospasm, and platelet aggregation (Reimer et al., 1986).

IHD in its various forms, is the leading cause of death in the united states and other industrialized nations and accounts for about 80% of all cardiac mortality. Annually, about 5 million individuals are diagnosed as having IHD, resulting in approximately 550,000 deaths, many more than all forms of cancer collectively (American Heart Association 1988).

The clinical expression of the various phases of coronary heart disease is not self limited or specific. In coronary heart disease,

therefore; the patient may present with or may develop any of the following :

- 1- Asymptomatic coronary disease, manifested by induced myocardial ischemia.
- 2- Sudden death.
- 3- Angina pectoris of effort, variant "prinzmetals" angina, coronary spasm.
- 4- Unstable angina pectoris "acute coronary insufficiency".
- 5- Acute myocardial infarction (Sokolow, 1990).

Risk factors for coronary artery disease :

1- Hyperlipidemia :

There is a well-established association between atherosclerosis and plasma cholesterol, but even stronger associations appear when the cholesterol carrying LDL and HDL lipoprotein fractions are considered. LDL-cholesterol levels are predictive of coronary heart disease, but an inverse relationship is seen with HDL-cholesterol, so that high levels appear to be protective.

Cholesterol deposited in atheromatous lesions is derived from LDL and enters the lesion at a rate dependent upon the plasma concentrations. The protective role of HDL may be in mediating hepatic cholesterol excretion by reverse transport of cholesterol from the periphery (Kumar, 1990). serum apolipoprotein A "HDL apoprotein" and apolipoprotein B" LDL apoprotein" were also

evaluated as potential indicators of risk of ischemic heart diseases (Durrington, 1986).

Lipoprotein (a) [LP (a)] is known to be an independent risk factor for coronary artery disease. Several studies suggest that high levels of LP (a) may suppress the profibrinolytic activity at the cell surface and increase the risks of arterio-sclerosis and thrombosis. It was recently reported that LP (a) like plasminogen can bind to fibrin and that it competes with plasminogen and tissue type plasminogen activator for fibrin binding. In addition, LP (a) attenuates the fibrin-dependent enhancement of tissue-type plasminogen activator activity against a native substrate, and in plasma milieu LP (a) inhibits clot lysis induced by tissue-type plasminogen activator (Eberhard et al., 1991).

2- Hypertension :

Hypertension increase the filtration of lipid from plasma to the intimal cell by virtue of increased arterial pressure, especially in the presence of elevated plasma lipids. Hypertension as well as hyperlipidemia may injure the intima, leading to platelet aggregation and proliferation of smooth muscle cells in the media.

Increased susceptibility to injury from shear forces, torsion, and lateral wall pressure changes may also be important.

Hypertension is now the most common and most important risk factor in the pathogenesis of atherosclerosis, atherosclerotic

complications constitute the most common cause of death in hypertensive patients (Sokolow, 1990).

3- Diabetes :

The asymptomatic hyperglycemia of adults with diabetes mellitus may be a risk factor independent of and additive to the effect of blood pressure and serum lipids.

Diabetes affects the capillary basement membrane "microangiopathy" of all tissues. It produces abnormalities in the myocardium, in small coronary vessels, and in the major arteries pathologically, atherosclerosis occurs more frequently and at an earlier age in diabetic patients (Waller, 1980). In subjects with impaired glucose tolerance, the mortality rate from coronary heart disease was approximately doubled as compared to that in patients with normal glucose tolerance after a 7.5 year period of observation (Fuller, 1986).

4- Family history :

A positive family history may reflect.

- 1- Genetic predisposition to the development of hypertension, hyperlipidemia, or diabetes or.
- 2- Environmental influences such as diet, stress and life-style.